 SAN DIEGO, California and CALGARY, Alberta , April 17, 2020 CNW -- Oncolytics Biotech Inc. ONCY ONC.TO, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided an update on the potential impact of COVID-19 on the Companys clinical and business operations. The Companys clinical and regulatory teams remain active and are working closely with our investigators to identify the most appropriate steps forward for each study. There has been no impact on the continuity of the manufacturing of pelareorep, and Oncolytics is fully capable of supplying pelareorep to all ongoing clinical studies. 